帕博利珠单抗用于T细胞非霍奇金淋巴瘤患者自体干细胞移植后的2期研究
这项2期多中心研究评估了外周T细胞淋巴瘤(PTCL)首次缓解期自体干细胞移植(ASCT)后使用帕博利珠单抗维持治疗。21例患者接受帕博利珠单抗200 mg静脉注射每3周一次最多8周期,18个月无进展生存(PFS)估计值为83.6%(95%CI 68-100),总生存为94.4%(95%CI 84-100),未出现5级毒性。作者认为该方案可行、安全性良好且活性有前景,支持进一步验证性研究。
要点
- ASCT后帕博利珠单抗200 mg每3周一次最多8周期,21例中67%(n=14)完成8周期。
- 18个月PFS估计值83.6%(95%CI 68-100),总生存94.4%(95%CI 84-100)。
- 毒性谱与帕博利珠单抗已知毒性一致,未出现5级毒性。
核心结论
- ASCT后使用帕博利珠单抗进行PD-1阻断可行,安全性良好且活性有前景,支持进一步验证性研究。
研究设计与样本
- 2期多中心研究,纳入PTCL首次缓解期ASCT后患者,帕博利珠单抗200 mg静脉注射每3周一次最多8周期,于ASCT出院后21天内(且干细胞输注后60天内)开始给药。
- 主要终点为ASCT后18个月无进展生存(PFS)。
- 共21例患者接受治疗。
主要发现
- 21例中67%(n=14)完成8周期治疗。
- 可评估患者中21例有13例在ASCT后18个月时存活且达到PFS,达到研究主要终点。
- 18个月PFS估计值为83.6%(95%CI 68-100),总生存为94.4%(95%CI 84-100)。
- 毒性谱与帕博利珠单抗已知毒性一致,未出现5级毒性。
关键数值与推荐
- 帕博利珠单抗给药方案:200 mg静脉注射,每3周一次,最多8周期。
- 给药时间窗:ASCT出院后21天内开始,且干细胞输注后60天内。
- 主要终点:ASCT后18个月PFS。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autologous stem cell transplantation (ASCT) is often used as consolidation for several subtypes of peripheral T-cell lymphoma (PTCL) in first remission. However, many patients relapse after ASCT and have a very poor prognosis. There are no approved treatment options for posttransplantation maintenance or consolidation in PTCL. PD-1 blockade has demonstrated some efficacy for patients with PTCL. We, therefore, conducted a phase 2 multicenter study of the anti-PD-1 monoclonal antibody pembrolizumab after ASCT in patients with PTCL in first remission. Pembrolizumab was administered at 200 mg IV every 3 weeks for up to 8 cycles within 21 days from post-ASCT discharge (and within 60 days of stem cell infusion). The primary end point was progression-free survival (PFS) at 18 months after ASCT. Twenty-one patients were treated in this study and 67% (n = 14) completed 8 cycles of treatment. Among all patients who were evaluable, 13 of 21 were alive and achieved PFS at 18 months after ASCT, meeting the study's primary end point. The estimated 18-month PFS was 83.6% (95% confidence interval [CI], 68-100), and overall survival 94.4% (95% CI, 84-100). The toxicity profile was consistent with the known toxicity profile of pembrolizumab, with no grade 5 toxicities. In conclusion, PD-1 blockade after ASCT with pembrolizumab is feasible with a favorable safety profile and promising activity, supporting further confirmatory studies. This trial was registered at www.clinicaltrials.gov as #NCT02362997.
引用
- Merrill MH, Dahi PB, Redd RA, et al. A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma. Blood. 2023. PMID: 37319432. doi:10.1182/blood.2023020244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。